Form 4 for ANIX Anixa Biosciences Inc
Accepted 2025-10-31 00:00:00 ET · period of report 2025-10-30 · accession 0001493152-25-020322 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-31 | 2025-10-30 | ANIX | KUMAR AMIT | CEO | F - Tax | $4.06 | -169.4K | 610.5K | -22% | -$687.9K |
| D | 2025-10-31 | 2025-10-30 | ANIX | KUMAR AMIT | CEO | M - OptEx | $2.92 | +200.0K | 779.9K | +34% | +$584.0K |
| D | 2025-10-31 | 2025-10-30 | ANIX | KUMAR AMIT | CEO | M - OptEx | $0.00 | -200.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-30 | F | D | 169,439 | $4.06 | 610,486 | D | — | — | |
| 2 | Common | Common Stock | 2025-10-30 | M | A | 200,000 | $2.92 | 779,925 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Buy) | 2025-10-30 | M | D | 200,000 | $0.00 | 0 | D | $2.92 · — to 2026-02-18 | 200,000 Common Stock | (F2) Right-To-Buy, pursuant to a stock option grant dated February 18, 2016. (F3) The option vested in 36 consecutive monthly installments beginning on March 31, 2016. |